skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Experimental effect of retinoic acids on apoptosis during the development of diabetic retinopathy

Case report

(2371) Views  (651) Full article downloads

Authors: Nami Nishikiori, Makoto Osanai, Hideki Chiba, Takashi Kojima, Shuichiro Inatomi, et al

Published Date March 2008 Volume 2008:2(1) Pages 233 - 235
DOI: http://dx.doi.org/10.2147/OPTH.S2420

Nami Nishikiori1,2, Makoto Osanai2, Hideki Chiba2, Takashi Kojima2, Shuichiro Inatomi1,2, Hiroshi Ohguro1, Norimasa Sawada2

Departments of 1Ophthalmology and 2Pathology, Sapporo Medical University School of Medicine

Purpose: This study was conducted to investigate whether retinoic acids (RAs) had any effect on apoptosis during the development of diabetic retinopathy.

Methods: To investigate whether RAs had any effect on apoptosis during the development of diabetic retinopathy, we housed 32 C57BL/6 male mice and induced diabetes in 24 by intra peritoneal injections of streptozotocin (STZ; Sigma, St Louis, MO) and treated 16 of the diabetic mice with the RAs, all-trans-retinoic acid (ATRA) (seven mice) and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido] benzoic acid (Am580) (nine mice). The other eight mice were used as diabetic controls. We then measured apoptosis in the retina by TdT-dUTP terminal nick-end labeling assay.

Results: RAs inhibited the apoptosis of retinal cells in diabetic retinopathy. Many apoptotic cells were observed in retinas of the eight diabetic control mice (mean value and SD: 37.8 ± 6.9), whereas when diabetic mice were treated with RAs, the number of apoptotic cells significantly decreased (mean value and SD: 9.9 ± 6.4 for the seven ATRA-treated diabetic mice and 9.8 ± 5.9 for the nine Am580-treated diabetic mice) (p < 0.05).

Conclusion: Treatment with RAs decreases apoptosis during the development of diabetic retinopathy.

Keywords: retinoic acids, apoptosis, diabetic retinopathy, glial cell line-derived neurotrophic factor






 

Other articles by Dr Nami Nishikiori



Readers of this article also read:

Evaluation of adherence to morning versus evening glaucoma medication dosing regimens
Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent
Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
Pupillography of automated swinging flashlight test in amblyopia
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Correlation of central corneal thickness and axial length to the optic disc and peripapillary atrophy among healthy individuals, glaucoma and ocular hypertension patients
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Erratum
Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice